Para-Aminobenzoic Acid (PABA)
OTHER NAME(S): 4-Aminobenzoic Acid, ABA, Acide 4-aminobenzoïque, Acide Aminobenzoïque, Acide p-aminobenzoïque, Acide Para-Amino-Benzoïque, Acide Paraaminobenzoïque, Acide Para-Aminobenzoïque, Acido Para Aminobenzoico, Aminobenzoate Potassium, Aminobenzoic Acid, Bacterial Vitamin H1, Ethyl Dihydroxypropyl Aminobenzoate, Glyceryl Paraaminobenzoate, Octyl Diemthyl PABA, P-Aminobenzoic Acid, PABA, Padamate O, Para-Aminobenzoate, Vitamin B10, Vitamin Bx, Vitamin H1, Vitamine B10, Vitamine Bactérienne H1, Vitamine Bx, Para-aminobenzoic acid, Para Aminobenzoic Acid, Para Amino Benzoic Acid, Para-aminobenzoic acid, Ácido Paraaminobenzoico (PABA), Acide para-aminobenzoïque (PABA)
Overview
Para-aminobenzoic acid (PABA) is a chemical that occurs naturally in the body. It is also found in several foods including grains, eggs, milk, and meat.
PABA is part of the folic acid molecule. It was once considered a B vitamin but is now considered a nonessential nutrient. PABA is used as a sunscreen because it can block ultraviolet (UV) radiation to the skin.
People use PABA for sunburn protection and for a disease that causes curved, painful erections (Peyronie disease). It is also used for hardening of skin and connective tissue (scleroderma), aging skin, infertility, and many other conditions, but there is no good scientific evidence to support these uses.
Uses
Effective for
- Sunburn. Applying PABA to the skin prevents sunburn. PABA is an FDA-approved sunscreen.
Possibly Effective for
- A disease that causes curved, painful erections (Peyronie disease). Taking PABA by mouth improves symptoms of Peyronie disease. PABA is FDA-approved for use in this condition.
Possibly Ineffective for
- Hardening of skin and connective tissue (scleroderma). Taking PABA by mouth doesn't seem to improve scleroderma. Although PABA is FDA-approved for scleroderma, there is only limited evidence that it is effective.
There is interest in using PABA for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.
Side Effects
When taken by mouth: PABA is possibly safe when used appropriately. It's FDA-approved for use and generally well-tolerated. Side effects might include nausea, vomiting, upset stomach, anorexia, and rash. PABA is possibly unsafe when used in high doses. Taking more than 12 grams daily can cause serious side effects, including liver and kidney problems.
When applied to the skin: PABA is likely safe. It's FDA-approved for use and generally well-tolerated.
Precautions
When taken by mouth: PABA is possibly safe when used appropriately. It's FDA-approved for use and generally well-tolerated. Side effects might include nausea, vomiting, upset stomach, anorexia, and rash. PABA is possibly unsafe when used in high doses. Taking more than 12 grams daily can cause serious side effects, including liver and kidney problems.
When applied to the skin: PABA is likely safe. It's FDA-approved for use and generally well-tolerated.
Pregnancy and breast-feeding: PABA is likely safe when applied to the skin during pregnancy or breast-feeding. But there isn't enough reliable information to know if PABA is safe to take by mouth when pregnant or breast-feeding. Stay on the safe side and avoid use.
Children: PABA is likely safe when applied to the skin for children. PABA is possibly safe for children when taken by mouth in doses of 220 mg/kg daily or less. But PABA is possibly unsafe when taken by mouth in higher doses.
Kidney disease: PABA might build up in the kidneys and make kidney disease worse.
Interactions
Moderate Interaction
Be cautious with this combination
- Antibiotics (Sulfonamide antibiotics) interacts with Para-Aminobenzoic Acid (PABA)PABA can decrease the effectiveness of certain antibiotics called sulfonamides.
- Cortisone interacts with Para-Aminobenzoic Acid (PABA)The body breaks down cortisone to get rid of it. PABA might decrease how quickly the body breaks down cortisone. Taking PABA by mouth and getting a cortisone shot might increase the effects and side effects of cortisone.
- Dapsone (Avlosulfon) interacts with Para-Aminobenzoic Acid (PABA)Dapsone is used as an antibiotic. PABA might decrease the effectiveness of dapsone for treating infections.
Dosing
PABA has most often been used by adults in doses of 12 grams by mouth daily in 4 to 6 divided doses. It has also been used by children in doses depending on weight. Potassium salt formulations of PABA are most common. PABA is also used in sunscreens applied to the skin.
References
- United States Pharmacopeial Convention, Inc., ed. Drug Information for the Health Care Professional. 19th ed. Englewood, CO: Micromedex Inc., 1999.
- Gennaro A. Remington: The Science and Practice of Pharmacy. 19th ed. Lippincott: Williams & Wilkins, 1996.
- Facts and Comparisons staff. Drug Facts and Comparisons. St Louis: Wolters Kluwer Company (updated monthly).
- Covington TR, et al. Handbook of Nonprescription Drugs. 11th ed. Washington, DC: American Pharmaceutical Association, 1996.
- Worobec S, LaChine A. Dangers of orally administered para-aminobenzoic acid. JAMA 1984;251:2348.
- Zarafonetis CJ, Dabich L, DeVol EB, et al. Potassium para-aminobenzoate and liver function test findings. J Am Acad Dermatol 1986;15:144-9.
- Carson CC. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective? Tech Urol 1997;3:135-9.
- Zarafonetis CJ, Dabich L, Skovronski JJ, et al. Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapy. Clin Exp Rheumatol 1988;6:261-8.
- Zarafonetis CJ, Dabich L, Negri D, et al. Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. J Clin Epidemiol 1988;41:193-205.
- Clegg DO, Reading JC, Mayes MD, et al. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. J Rheumatol 1994;21:105-10.
- Zarafonetis CJ, Dabich L, Devol EB, et al. Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacity. Respiration 1989;56:22-33.
- Ludwig G. Evaluation of conservative therapeutic approaches to Peyronie's disease (fibrotic induration of the penis). Urol Int 1991;47:236-9.
- Hughes CG. Oral PABA and vitiligo. J Am Acad Dermatol 1983;9:770.
- Kantor GR, Ratz JL. Liver toxicity from potassium para-aminobenzoate. J Am Acad Dermatol 1985;13:671-2.
- Wiesel LL, Barritt AS, Stumpe WM. The synergistic action of para-aminobenzoic acid and cortisone in the treatment of rheumatoid arthritis. Am J Med Sci 1951;243-8.
- Zarafonetis CJ, Horrax TM. Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTOBA). J Urol 1959;81:770-2.
- Pathak MA. Sunscreens: Topical and systemic approaches for protection of human skin against harmful effects of solar radiation. J Am Acad Dermatol 1982;7:285-312.
- Zarafonetis CJ. Darkening of gray hair during para-amino-benzoic acid therapy. J Invest Dermatol 1950;399-401.
- Sieve BF. The clinical effects of a new B Complex Factor, para-aminobenzoic acid, on pigmentation and fertility. Southern Medicine & Surgery 1942;135-9.
- Jakobsen J, Pedersen AN, Ovesen L. Para-aminobenzoic acid (PABA) used as a marker for completeness of 24 hour urine: effects of age and dosage scheduling. Eur J Clin Nutr 2003;57:138-42.
- Petri, H., Pierchalla, P., and Tronnier, H. [The efficacy of drug therapy in structural lesions of the hair and in diffuse effluvium--comparative double blind study]. Schweiz.Rundsch.Med Prax. 11-20-1990;79(47):1457-1462.
- Mackie, B. S. and Mackie, L. E. The PABA story. Australas.J Dermatol 1999;40(1):51-53.
- Akberova, S. I., Tazulakhova, E. B., Musaev Galbinur, P. I., Leont'eva, N. A., and Stroeva, O. G. [Study of interferon-inducing activity of para-aminobenzoic acid injected subconjunctivally in rabbits]. Vestn.Oftalmol. 1999;115(1):24-26.
- Stroeva, O. G., Akberova, S. I., Drozd, N. N., Makarov, V. A., Miftakhova, N. T., and Kalugin, S. S. [The antithrombotic activity of para-aminobenzoic acid in experimental thrombosis]. Izv.Akad.Nauk Ser.Biol 1999;(3):329-336.
- Drozd, N. N., Makarov, V. A., Miftakhova, N. T., Kalugin, S. A., Stroeva, O. G., and Akberova, S. I. [Antithrombotic activity of para-aminobenzoic acid]. Eksp.Klin.Farmakol. 2000;63(3):40-44.
- Akberova, S. I. and Musaev Galbinur, P. I. [The new interferon inducer Aktipol in the treatment of herpetic keratitis]. Vestn.Oftalmol. 2000;116(2):16-18.
- Grouls, R., Korsten, E., Ackerman, E., Hellebrekers, L., van Zundert, A., and Breimer, D. Diffusion of n-butyl-p-aminobenzoate (BAB), lidocaine and bupivacaine through the human dura-arachnoid mater in vitro. Eur.J.Pharm.Sci. 2000;12(2):125-131.
- Akberova, S. I., Musaev Galbinur, P. I., Stroeva, O. G., Magomedov, N. M., Babaev, N. F., and Galbinur, A. P. [Comparative evaluation of the antioxidant activity of para-aminobenzoic acid and emoxipin in the cornea and crystalline lens (an experimental study)]. Vestn.Oftalmol. 2001;117(4):25-29.
- Akberova, S. I. [Actipol in treating stromal herpetic keratitis]. Vestn.Oftalmol. 2002;118(2):17-19.
- Akberova, S. I. [Para-aminobenzoic acid and prospects of its use in ophthalmology]. Vestn.Oftalmol. 2002;118(3):53-56.
- Taneva, E. [Pantogar--modern treatment of hair loss, structural hair lesions, early alopecia, and dystrophy of nails]. Akush.Ginekol.(Sofiia) 2002;41 Suppl 1:37-40.
- Beekwilder, J. P., O'Leary, M. E., van den Broek, L. P., van Kempen, G. T., Ypey, D. L., and van den Berg, R. J. Kv1.1 channels of dorsal root ganglion neurons are inhibited by n-butyl-p-aminobenzoate, a promising anesthetic for the treatment of chronic pain. J.Pharmacol.Exp.Ther. 2003;304(2):531-538.
- Griffiths, M. R. and Priestley, G. C. A comparison of morphoea and lichen sclerosus et atrophicus in vitro: the effects of para-aminobenzoate on skin fibroblasts. Acta Derm.Venereol. 1992;72(1):15-18.
- Zarafonetis, C. J. and HORRAX, T. M. Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J Urol. 1959;81(6):770-772.
- Leonard, F. and Kalis, B. [Photoprotection by drugs]. Rev Prat. 6-1-1992;42(11):1375-1376.
- Priestley, G. C. and Brown, J. C. Effects of potassium para-aminobenzoate on growth and macromolecule synthesis in fibroblasts cultured from normal and sclerodermatous human skin, and rheumatoid synovial cells. J.Invest Dermatol. 1979;72(4):161-164.
- Weidner, W., Hauck, E. W., and Schnitker, J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005;47(4):530-535.
- Pryor, J., Akkus, E., Alter, G., Jordan, G., Lebret, T., Levine, L., Mulhall, J., Perovic, S., Ralph, D., and Stackl, W. Peyronie's disease. J Sex Med. 2004;1(1):110-115.
- Rooney, J. F., Bryson, Y., Mannix, M. L., Dillon, M., Wohlenberg, C. R., Banks, S., Wallington, C. J., Notkins, A. L., and Straus, S. E. Prevention of ultraviolet-light-induced herpes labialis by sunscreen. Lancet 12-7-1991;338(8780):1419-1422.
- Gaby, A. R. Natural remedies for scleroderma. Altern.Med.Rev. 2006;11(3):188-195.
- Trost, L. W., Gur, S., and Hellstrom, W. J. Pharmacological Management of Peyronie's Disease. Drugs 2007;67(4):527-545.
- Korsten, H. H., Ackerman, E. W., Grouls, R. J., van Zundert, A. A., Boon, W. F., Bal, F., Crommelin, M. A., Ribot, J. G., Hoefsloot, F., and Slooff, J. L. Long-lasting epidural sensory blockade by n-butyl-p-aminobenzoate in the terminally ill intractable cancer pain patient. Anesthesiology 1991;75(6):950-960.
- Pan, C. W., Shen, Z. J., and Ding, G. Q. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study. J Urol. 2008;179(4):1307-1311.
- Pereira de Godoy, J. M. Aminaphtone in idiopathic cyclic oedema syndrome. Phlebology. 2008;23(3):118-119.
- Antoniou, C., Kosmadaki, M. G., Stratigos, A. J., and Katsambas, A. D. Sunscreens--what's important to know. J Eur Acad.Dermatol Venereol. 2008;22(9):1110-1118.
- Fisher, D. E., Lofton, S. P., Hale, T., Durant, N., and Grant, L. F. Peyronie's disease: a case study with clinical implications. Urol.Nurs. 2008;28(2):109-112.
- Hellstrom, W. J. Medical management of Peyronie's disease. J Androl 2009;30(4):397-405.
- Flindt-Hansen, H. and Ebbesen, P. Ultraviolet light induction of peripheral granulocytosis with splenomegaly: protection of mice with topical p-aminobenzoic acid (PABA). Br J Dermatol 1991;125(3):222-226.
- Flindt-Hansen, H., Thune, P., and Eeg-Larsen, T. The effect of short-term application of PABA on photocarcinogenesis. Acta Derm.Venereol. 1990;70(1):72-75.
- Alenda, O., Beley, S., Ferhi, K., Cour, F., Chartier-Kastler, E., Haertig, A., Richard, F., and Roupret, M. [Pathophysiology and management of Peyronie's disease in adult patients: an update]. Prog Urol. 2010;20(2):91-100.
- Gur, S., Limin, M., and Hellstrom, W. J. Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options. Expert.Opin.Pharmacother. 2011;12(6):931-944.
- Larsen, S. M. and Levine, L. A. Peyronie's disease: review of nonsurgical treatment options. Urol.Clin North Am 2011;38(2):195-205.
- Flindt-Hansen, H., Thune, P., and Larsen, T. E. The inhibiting effect of PABA on photocarcinogenesis. Arch.Dermatol Res 1990;282(1):38-41.
- Taylor, C. R., Stern, R. S., Leyden, J. J., and Gilchrest, B. A. Photoaging/photodamage and photoprotection. J Am Acad.Dermatol 1990;22(1):1-15.
- Taylor, S. E. and Dorris, R. L. Modification of local anesthetic toxicity by vasoconstrictors. Anesth.Prog 1989;36(3):79-87.
- Hasche-Klunder, R. [Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTOBA) (author's transl)]. Urologe A 1978;17(4):224-227.
- Kierkegaard, E. and Nielsen, B. [Peyronie's disease treated with K-para-aminobenzoate and vitamin E]. Ugeskr.Laeger 7-23-1979;141(30):2052-2053.
- Abarca, J., Odilla, Arrollo C., Blanch, S., and Arellano, G. [Melasma in pregnancy: reduction of its appearance with the use of a broad-spectrum photoprotective agent]. Med Cutan.Ibero.Lat.Am 1987;15(3):199-203.
- Slapke, J., Hummel, S., Wischnewsky, G. G., and Winkler, J. Protease inhibitor prevents bronchoconstriction in man. Eur J Respir.Dis 1986;68(1):29-34.
- Hoek, F. J., Sanders, G. T., and Tytgat, G. N. Influence of gastric emptying on the PABA test. Clin Chim Acta 6-15-1987;165(2-3):235-241.
- Davies, D. M. and Cavanagh, J. Jaundice from potassium p-aminobenzoate. Lancet 4-22-1967;1(7495):896.
- Mohorn, M. and Knupfer, M. [Effectiveness of the calcium antagonist nifedipine and the protease inhibitor with plasmin inactivating effect para-aminomethylbenzoic acid on stress-induced bronchial asthma]. Z Gesamte Inn.Med 11-1-1984;39(21):527-530.
- Jarratt, M., Hill, M., and Smiles, K. Topical protection against long-wave ultraviolet A. J Am Acad.Dermatol 1983;9(3):354-360.
- Penneys, N. S. Treatment of lichen sclerosus with potassium para-aminobenzoate. J.Am.Acad.Dermatol. 1984;10(6):1039-1042.
- van den Berg, R. J., Van Soest, P. F., Wang, Z., Grouls, R. J., and Korsten, H. H. The local anesthetic n-butyl-p-aminobenzoate selectively affects inactivation of fast sodium currents in cultured rat sensory neurons. Anesthesiology 1995;82(6):1463-1473.
- Sagone, A. L., Jr., Husney, R. M., and Davis, W. B. Biotransformation of para-aminobenzoic acid and salicylic acid by PMN. Free Radic.Biol.Med. 1993;14(1):27-35.
- Duffy, L. F., Kerzner, B., Seeff, L., Barr, S. B., and Soldin, S. J. Preliminary assessment of glycine conjugation of para-aminobenzoic acid as a quantitative test of liver function. Clin.Biochem. 1995;28(5):527-530.
- Dobrev, H., Popova, L., and Vlashev, D. Proteinase inhibitors and pemphigus vulgaris. An in vitro and in vivo study. Arch Dermatol Res 1996;288(11):648-655.
- Ehlert, C., Strunz, H., Visser, K., Wiese, M., and Seydel, J. K. Inhibition of the conjugation of PABA with glycine in vitro by sulfamoyl benzoic acids, sulfonamides, and penicillins and its relation to tubular secretion. J Pharm.Sci 1998;87(6):785.
- Linn, E. E. Microemulsion of intradermal delivery of cetyl alcohol and octyl dimethyl PABA. Drug Development & Industrial Pharmacy 1990;16(6):899-920.